Products

Quantitative Total Extensible Imaging (QTxI)
AIQ Solutions
Oncology AI
Quantitative Total Extensible Imaging (QTxI) is an FDA-cleared software tool by AIQ Solutions for medical professionals to evaluate and manage digital medical images (DICOM CT and PET), enabling quantitative analysis of Regions of Interest for improved treatment monitoring, particularly in oncology.
TRAQinform IQ
AIQ Solutions
Oncology AI
TRAQinform IQ is an FDA-cleared, cloud-based AI software tool that provides quantitative analysis of lesions in PET/CT scans, aiding clinicians in monitoring disease progression and treatment response in oncology and nuclear medicine.

See all 2 products →

About AIQ Solutions

AIQ Solutions is a commercial-stage medical device company that leverages quantitative imaging and artificial intelligence to enhance treatment outcomes for patients with complex diseases, particularly late-stage cancer. Their core offering is the TRAQinform IQ software platform, an FDA-cleared clinical decision support tool designed for oncologists, radiologists, and nuclear medicine specialists. This technology analyzes PET and CT scan images to automatically detect, segment, and quantify cancerous lesions throughout the body.

The TRAQinform IQ platform provides detailed reports and 3D visualizations that map out how individual tumors respond to therapy over time, highlighting areas of progression, regression, or stability. This capability allows clinicians to move beyond assessing only a few sample lesions, offering a holistic view of the patient’s total disease burden. By addressing the critical challenge of tumor heterogeneity—where different tumors in the same patient may respond variedly to treatment—AIQ Solutions enables more personalized and timely adjustments to treatment plans, ultimately aiming to improve clinical outcomes and reduce healthcare costs.

Focus Areas

Oncology Artificial Intelligence Machine Learning Digital Health Big Data HealthTech Life Sciences Medical Devices Imaging Biomarkers Treatment Response Assessment

Business Intelligence

TechnologyQTS (Quantitative Total-body Imaging Solutions) Platform, AI-powered medical device software, cloud-native

What Physicians Need to Know

Specialization
AIQ Solutions specializes in advanced software solutions for managing complex diseases, particularly late-stage cancer, using medical imaging and artificial intelligence. Their core product, the QTS (Quantitative Total-body Imaging Solutions) Platform, provides detailed, quantitative analyses of imaging data to aid in treatment decisions.
Key Differentiator: Treatment Response Heterogeneity
AIQ Solutions addresses the critical challenge of tumor heterogeneity, where different tumors in the same patient may respond differently to treatment. Their TRAQinform IQ software analyzes PET and CT scans to automatically detect, segment, and quantify cancerous lesions body-wide, providing a holistic view of the patient's total disease burden.
Key Differentiator: Quantitative Imaging Biomarkers
The company provides unique intelligence about the heterogeneity of treatment response through quantitative imaging biomarkers. This allows clinicians to make better-informed therapy decisions, potentially improving clinical outcomes and reducing healthcare costs.
Technology Stack
AIQ Solutions leverages AI/Machine Learning for predictive modeling, quantitative image analysis, radiomics, and longitudinal lesion tracking. Their platform utilizes cloud-based, HIPAA-compliant data pipelines for remote processing of serial PET/CT and other radiographic studies.
FDA Cleared
AIQ Solutions' software has received FDA 510(k) clearance for clinical use in monitoring several specific types of cancer, including lung, prostate, and lymphoma.
Clinical Decision Support
Their TRAQinform IQ software platform is a clinical decision support tool for oncologists, radiologists, and nuclear medicine specialists, providing comprehensive reports and 3D visualizations of tumor response to therapy over time.
Physician Tip

For physicians, AIQ Solutions' TRAQinform IQ technology offers a powerful tool to move beyond assessing a few sample lesions. It provides a comprehensive, lesion-level understanding of treatment response, highlighting areas of progression, regression, or stability across all tumors. This enables more personalized and timely adjustments to treatment plans, potentially leading to optimized clinical outcomes, especially in late-stage cancer where intra-patient heterogeneity is common. The cloud-based system and FDA clearance ensure a streamlined and reliable workflow for integrating advanced imaging analytics into existing clinical practices.

AIQ Solutions' TRAQinform IQ technology is designed for easy integration into existing clinical workflows, utilizing serial radiographic images (e.g., PET, CT). Images are uploaded via a HIPAA-compliant cloud to AIQ Solutions, and a comprehensive report is generated and delivered to the oncologist. They also offer platform integration with research data management systems for scalable workflows.

Products by AIQ Solutions

2 products in the directory

Quantitative Total Extensible Imaging (QTxI)
AIQ Solutions
Oncology AI
Quantitative Total Extensible Imaging (QTxI) is an FDA-cleared software tool by AIQ Solutions for medical professionals to evaluate and manage digital medical images (DICOM CT and PET), enabling quantitative analysis of Regions of Interest for improved treatment monitoring, particularly in oncology.
TRAQinform IQ
AIQ Solutions
Oncology AI
TRAQinform IQ is an FDA-cleared, cloud-based AI software tool that provides quantitative analysis of lesions in PET/CT scans, aiding clinicians in monitoring disease progression and treatment response in oncology and nuclear medicine.

What the Web Says

AIQ Solutions (also referred to as AIQ, AIQ Management, and Alpine IQ in reviews) receives generally positive feedback for its product offerings, particularly its AI capabilities, user-friendly interface, and efficient data management. Employer reviews also indicate a positive work environment with high ratings for work-life balance, pay and benefits, management, and culture. However, some users have expressed frustration with specific product functionalities and customer service responsiveness.

Overall: Positive

Strengths

  • AI capabilities and real-time data integration are highly valued.
  • User-friendly interface and ease of integration.
  • Automated marketing campaigns and advanced segmentation features.
  • Strong focus on operational efficiency, resource optimization, and security.
  • Positive work-life balance, pay, and benefits for employees.
  • Supportive management and positive company culture.

Limitations

  • Some users have experienced issues with specific product functionalities, such as obtaining accurate last cost information.
  • One review mentioned a negative experience with the software, calling it the 'worst program on Earth'.
  • Lack of recent history of inviting customer reviews on Trustpilot, potentially leading to a less representative sample of opinions.
  • Limited detailed negative product reviews available across major platforms.
  • One Trustpilot review indicated the company 'hasn't replied to negative reviews'.

Based on reviews from: G2, Indeed.com, Capterra, Trustpilot

Last updated: 2026-10-22

Videos

News, demos, and interviews about AIQ Solutions.

Loading videos...

Videos load interactively. If none appear, search YouTube for AIQ Solutions →

View all on YouTube

Press & Coverage

AIQ Solutions
AIQ Solutions Secures $134K Funding to Innovate Complex Disease Treatment Worldwide
AIQ Solutions announced a funding milestone of $134,800 to accelerate research and development, enhance technological infrastructure, and expand clinical trials for complex disease management. This capital infusion will also support forging key partnerships with healthcare providers and research institutions.
2025-05
PR Newswire
AIQ Solutions Announces a New Category III CPT Code for Determining Heterogeneity of Change Across All Lesions for Advanced Metastatic Cancer Used with TRAQinform IQ Technology
AIQ Solutions announced that the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code for its TRAQinform IQ technology, which helps analyze treatment response in late-stage cancer. This code is a significant step towards broader clinical adoption and recognition of the platform's unique analysis.
2026-03
AIQ Global
AIQ Solutions Awarded Its Sixth Patent
AIQ Solutions secured its sixth patent for its AI-enabled late-stage cancer analysis technology (U.S. Patent No. 12,562,258). These patents protect the foundational capabilities and represent future innovations for their TRAQinform IQ product.
2026-04
OncoDaily
AIQ Solutions Tackles the Complex Reality of Unequal Metastatic Cancer Treatment Responses - CancerX - OncoDaily
AIQ Solutions is addressing a critical gap in advanced cancer care by developing pioneering technology that quantifies treatment response for individual lesions and organs in metastatic cancer patients. This personalized approach aims to improve treatment predictions and adjustments.
2025-04
Journal of Clinical Medicine (MDPI)
Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT
This publication discusses the clinical meaningfulness of an algorithm-based service by AIQ Solutions for analyzing treatment response in metastatic cancer patients using FDG PET/CT. The study highlights the importance of advanced image analysis in assessing treatment efficacy.
2024-10
AIQ Global
AIQ Solutions Featured as Small Business Success Story by Wisconsin Economic Development Corporation (WEDC)
AIQ Solutions was featured by the WEDC for its success in developing a faster and more comprehensive way to analyze multiple radiological images for late-stage cancer patients. Their technology is now used in several U.S. hospitals and in Australia.
2024-01
AIQ Global
Blackford and AIQ Solutions Announce Commercial Partnership to Bring Advanced Clinical Decision Support Tools for Metastatic Cancer to Healthcare Providers
AIQ Solutions partnered with Blackford Analysis to integrate its clinical decision support technology for metastatic cancer into Blackford's enterprise AI platform. This collaboration aims to expand access to AIQ's innovative tools for oncologists and other healthcare professionals.
2023-11
AIQ Global
AIQ SOLUTIONS AWARDED $2M PHASE II NIH SBIR GRANT TO ADVANCE DEVELOPMENT AND COMMERCIALIZATION OF A BIOMARKER TECHNOLOGY THAT PREDICTS CANCER IMMUNOTHERAPY RESPONSE
AIQ Solutions received a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop and commercialize technology for analyzing and predicting treatment response in metastatic cancer patients undergoing immunotherapy.
2022-05

Frequently Asked Questions

AIQ Solutions addresses the challenge of assessing treatment response heterogeneity in late-stage cancer patients. Their TRAQinform IQ™ software analyzes serial radiographic images (e.g., PET/CT) to quantify changes in individual lesions over time, providing oncologists with detailed, quantitative information to help tailor treatment regimens and optimize outcomes.
AIQ Solutions' core product is the TRAQinform IQ™ software platform, a clinical decision support tool. It leverages AI and machine learning to analyze medical imaging data, such as PET and CT scans, to automatically detect, segment, and quantify cancerous lesions body-wide. This provides detailed reports and 3D visualizations that map individual tumor responses to therapy, moving beyond assessing just a few sample lesions to offer a holistic view of the patient's total disease burden.
AIQ Solutions states that its TRAQinform IQ™ software is FDA 510(k)-cleared for clinical use. They also emphasize that images uploaded via the cloud to AIQ Solutions are HIPAA compliant, and they have compliance policies, including an FCOI Policy and Privacy Policy for Australia, available for review.
While specific pricing for AIQ Solutions' oncology products is not publicly detailed, other AIQ entities offer various pricing models. Some AIQ services use a per-clinician SaaS model, usage-based billing, enterprise bundles, or hybrid contracts, with some AI medical scribe pricing ranging from $29-$1,200/month per clinician. It is recommended to contact AIQ Solutions directly for specific pricing related to their oncology imaging analysis software.
AIQ Solutions offers cloud-based lesion-level image analysis and reporting, remote processing of serial PET/CT studies, and clinician-facing reports delivered via secure cloud workflows. They also provide research collaborations and clinical validation support. AIQ Solutions has partnered with companies like Flywheel to offer data management and analysis solutions, and Blackford Analysis to integrate their clinical decision support technology into Blackford's enterprise AI platform.
AIQ Solutions was founded in 2015, based on 15 years of research from the University of Wisconsin. They are a commercial-stage medical device company with offices in Madison, Wisconsin, and Perth, Australia. The company has raised over $20 million in total equity funding from venture capital investors. AIQ Solutions aims for its technology to become a standard of care in oncology, indicating strong growth aspirations within HealthTech and Life Sciences.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.